What is Sagimet Biosciences Inc.'s (SGMT) StockRank?

MoatMap's StockRank for Sagimet Biosciences Inc. (SGMT) is 27/100, with a Sell signal. This is a composite score combining Quality (41), Value (29), and Momentum (47) factor ranks across MoatMap's 19,000+ stock universe.

Does Sagimet Biosciences Inc. have an economic moat?

Sagimet Biosciences Inc. (SGMT) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Sagimet Biosciences Inc. a buy, hold, or sell?

MoatMap's current signal for Sagimet Biosciences Inc. (SGMT) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Sagimet Biosciences Inc. in?

Sagimet Biosciences Inc. (SGMT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SGMT

SELLREMOVE

Sagimet Biosciences Inc. · Healthcare · United States · $449M · Avg Vol: $5M/d

StockRank

P/E (TTM)

—

ROE

-36.0%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Sagimet Biosciences is a clinical-stage biotech developing denifanstat for MASH. It is a binary clinical trial play that lacks the structural, high-utilization manufacturing moat of a CDMO.

COMPANY DESCRIPTION

Sagimet Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic diseases. The company's lead product candidate targets fatty acid synthase (FASN) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Sagimet operates in the highly competitive pharmaceutical industry, aiming to carve out a niche with its differentiated approach to fatty acid metabolism for liver disease and other conditions.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	2M	0	0	—
EPS	-1.10	-1.38	-2.66	-1.45	—	—
Shares	—	22M	23M	32M	33M	+46.7%
Debt	—	211,000	65,000	78,000	78,000	-28.2%
Equity	—	-187M	91M	156M	111M	10.6%
Op CF	—	-24M	-24M	-42M	-46M	—
Inv CF	—	-32M	13M	-62M	5M	—
Fin CF	—	-73,000	86M	105M	275,000	—

PRICE (1M)-18.1%

SMA 50SMA 200

$6.47

RSI (14)

25.5

52W High

$11.41

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-51.1%13.5

ROE

-36.0%22.7

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-23.7%13.5

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.00x98.7

Current Ratio

20.34x95.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

2.1x54.4

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

57%34.3

RS 6M

-6%72.9

SMA 50/200

1.04x70.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+3%22.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$449M

P/E (Forward)

-4.9x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGMT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SGMT	Sagimet Biosciences Inc.(you)	$449M	27	SELL
STTK	Shattuck Labs, Inc.	$458M	30	SELL
GLSI	Greenwich LifeSciences, Inc.	$402M	28	SELL
FDMT	4D Molecular Therapeutics, Inc.	$469M	30	SELL
ENTA	Enanta Pharmaceuticals, Inc.	$385M	28	SELL
BNTC	Benitec Biopharma Inc.	$397M	29	SELL
KYTX	Kyverna Therapeutics, Inc.	$526M	24	SELL
LRMR	Larimar Therapeutics, Inc.	$363M	23	SELL
ACHV	Achieve Life Sciences, Inc.	$544M	31	SELL
PRTC.L	PureTech Health plc	$455M	35	SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Sagimet Biosciences Inc. (SGMT) — Stock Score Summary

Sagimet Biosciences Inc. (SGMT) has a MoatMap StockRank of 27/100 based on Quality (41/100), Value (29/100), and Momentum (47/100) factor scores. The current signal is SELL. Sagimet Biosciences is a clinical-stage biotech developing denifanstat for MASH. It is a binary clinical trial play that lacks the structural, high-utilization manufacturing moat of a CDMO.

Key Financial Metrics

Price	$6.47
Market Cap	$449M
P/E (Forward)	-4.94
Price/Book	2.06
Return on Equity	-36.0%
Return on Invested Capital	-51.1%
Debt/Equity	0.04
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-28M

Sagimet Biosciences Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Sagimet Biosciences Inc.’s (SGMT) StockRank?: MoatMap’s StockRank for Sagimet Biosciences Inc. (SGMT) is 27/100, with a Sell signal. It is a composite of Quality (41), Value (29), and Momentum (47) factor ranks across MoatMap’s 19,000+ stock universe.
Does Sagimet Biosciences Inc. have an economic moat?: Sagimet Biosciences Inc. (SGMT) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sagimet Biosciences Inc. a buy, hold, or sell?: MoatMap’s current signal for Sagimet Biosciences Inc. (SGMT) is Sell, based on a StockRank of 27/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Sagimet Biosciences Inc. in?: Sagimet Biosciences Inc. (SGMT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).